Pancreatic autoantibodies (PAbs) have been suggested as a specific but not sensitive marker for Crohn’ s disease (CD). The aim of this study was to assess the value of detecting PAbs in Greek patients with ulcerative colitis (UC) and CD. Sera were collected from 150 patients with IBD (73 with UC and 77 with CD), 31 cases with non-IBD intestinal inflammation, 16 cases with other autoimmune diseases, and 104 healthy controls. Determination of PAbs was performed by a standard indirect immunofluorescence technique. PAbs were detected in 18 of 73 (24.7% ) samples from UC patients and in 32 of 77 (41.6% ) samples from CD patients. The prevalence of positive PAbs was significantly higher in CD than in UC (P = 0.04). None of the 104 samples from healthy controls and the 31 cases with non-IBD intestinal inflammation had detectable PAbs. One patient with Sjogren’ s syndrome was PAbs positive. No association of PAbs with IBD activity, IBD localization, or medical treatment was found. Patients with stenotic CD had a significantly higher prevalence of PAbs positivity (60% ) compared with patients with inflammatory (28.6% ) and fistulizing (41.2% ) disease (P = 0.02). The prevalence of PAbs in Greek CD patients was found to be similar to that in previous reports. In contrast to these studies we found also increased prevalence of PAbs in UC patients. These findings suggest that PAbs should be considered as a specific marker for IBD rather than for CD. The aim of this study was to assess the value of detecting PAbs in Greek patients with ulcerative colitis (UC) and CD. Sera. Pancreatic autoantibodies (PAbs) have been suggested as a specific but not sensitive marker for Crohn’s disease were collected from 150 patients with IBD (73 with UC and 77 with CD), 31 cases with non-IBD intestinal inflammation, 16 cases with other autoimmune diseases, and 104 healthy controls. Determination of PAbs was performed by a standard indirect immunofluorescence technique. The prevalence of the positive PAbs was significantly higher in CD than in UC (P = 0.04). None of of the PAbs were significantly higher in CD than in UC (P = 0.04). None of the PAbs were detected in 18 of 73 (24.7%) samples from UC patients and in 32 of 77 the 104 samples from healthy controls and the 31 cases with non-IBD intestinal inflammation had detectable PAbs. One patient with Sjogren’s syndrome was PAbs positive. No association of PAbs with IBD activity, IBD localization, or medical treatment was found. Patients wit The prevalence of PAbs in Greek CD patients was found to be similar (60%) compared with patients with inflammatory (28.6%) and fistulizing (41.2%) disease (P = 0.02) To that in previous reports. In contrast to these studies we found also increased prevalence of PAbs in UC patients. These findings suggest that PAbs should be considered as a specific marker for IBD rather than for CD.